Interstitial Lung Disease Market, by Disease Type (Interstitial Pneumonia, Idiopathic Pulmonary Fibrosis, Nonspecific Interstitial Pneumonitis, Hypersensitivity Pneumonitis, Cryptogenic Organizing Pneumonia (COP), Sarcoidosis, and Acute Interstitial Pneum

Interstitial Lung Disease Market, by Disease Type (Interstitial Pneumonia, Idiopathic Pulmonary Fibrosis, Nonspecific Interstitial Pneumonitis, Hypersensitivity Pneumonitis, Cryptogenic Organizing Pneumonia (COP), Sarcoidosis, and Acute Interstitial Pneumonitis), by Drug Type (Corticosteroids, Anti-fibrotic Medication, Pirfenidone, and Nintedanib), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Interstitial lung disease (ILD) is a term used for group of diseases that cause scarring (fibrosis) of the lungs. This scarring causes stiffness in the lungs, which makes difficult to breathe and supply oxygen to the bloodstream. Interstitial lung disease can be caused due to long-term exposure to hazardous materials such as asbestos. Some types of autoimmune diseases, such as rheumatoid arthritis, also can cause interstitial lung disease. The symptoms of interstitial lung disease include:
Shortness of breath at rest
Dry cough
The diseases which are grouped under interstitial lung disease are interstitial pneumonia, idiopathic pulmonary fibrosis, nonspecific interstitial pneumonitis, hypersensitivity pneumonitis, cryptogenic organizing pneumonia (COP), sarcoidosis, and acute interstitial pneumonitis. Interstitial lung disease (ILD) can be treated with medications such as corticosteroids, anti-fibrotic medication, Pirfenidone, and nintedanib.

Market Dynamics

Increasing number of drug approvals from regulatory bodies is expected to drive the growth of global interstitial lung disease market during the forecast period. For instance, in October 2014, the U.S. Food and Drug Administration (FDA) approved pirfenidone (Esbriet) and nintedanib (Ofev) for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease that makes breathing difficult and causes irreversible lung damage.

Increasing number of drug launches is expected to drive the growth of global interstitial lung disease market. For instance, in October 2021, Glenmark Pharmaceuticals, a research-led, global integrated pharmaceutical company, announced the launch of NINDANIB (Nintedanib 100 and 150 mg capsules) for the treatment of pulmonary fibrosis in India.

Key features of the study:
This report provides an in-depth analysis of global interstitial lung disease market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global interstitial lung disease market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans.
Key companies covered as a part of this study include MSD (Merck), Liminal Biosciences, Glenmark Pharma, J.B. Chemicals & Pharmaceuticals, Boehringer Ingelhim International GmbH, F. Hoffmann-La Roche Ltd., and Cipla
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
The global interstitial lung disease market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision making through various strategy matrices used in analyzing the interstitial lung disease market.
Detailed Segmentation:
Global Interstitial Lung Disease Market, By Disease Type:
Interstitial Pneumonia
Idiopathic Pulmonary Fibrosis
Nonspecific Interstitial Pneumonitis
Hypersensitivity Pneumonitis
Cryptogenic Organizing Pneumonia (COP)
Sarcoidosis
Acute Interstitial Pneumonitis
Global Interstitial Lung Disease Market, By Drug Type:
Corticosteroids
Anti-fibrotic Medication
Pirfenidone
Nintedanib
Global Interstitial Lung Disease Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Interstitial Lung Disease Market, By Region:
North America
By Disease Type:
Interstitial Pneumonia
Idiopathic Pulmonary Fibrosis
Nonspecific Interstitial Pneumonitis
Hypersensitivity Pneumonitis
Cryptogenic Organizing Pneumonia (COP)
Sarcoidosis
Acute Interstitial Pneumonitis
By Drug Type:
Corticosteroids
Anti-fibrotic Medication
Pirfenidone
Nintedanib
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
U.S.
Canada
Latin America
By Disease Type:
Interstitial Pneumonia
Idiopathic Pulmonary Fibrosis
Nonspecific Interstitial Pneumonitis
Hypersensitivity Pneumonitis
Cryptogenic Organizing Pneumonia (COP)
Sarcoidosis
Acute Interstitial Pneumonitis
By Drug Type:
Corticosteroids
Anti-fibrotic Medication
Pirfenidone
Nintedanib
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Disease Type:
Interstitial Pneumonia
Idiopathic Pulmonary Fibrosis
Nonspecific Interstitial Pneumonitis
Hypersensitivity Pneumonitis
Cryptogenic Organizing Pneumonia (COP)
Sarcoidosis
Acute Interstitial Pneumonitis
By Drug Type:
Corticosteroids
Anti-fibrotic Medication
Pirfenidone
Nintedanib
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
Asia Pacific
By Disease Type:
Interstitial Pneumonia
Idiopathic Pulmonary Fibrosis
Nonspecific Interstitial Pneumonitis
Hypersensitivity Pneumonitis
Cryptogenic Organizing Pneumonia (COP)
Sarcoidosis
Acute Interstitial Pneumonitis
By Drug Type:
Corticosteroids
Anti-fibrotic Medication
Pirfenidone
Nintedanib
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
Middle East
By Disease Type:
Interstitial Pneumonia
Idiopathic Pulmonary Fibrosis
Nonspecific Interstitial Pneumonitis
Hypersensitivity Pneumonitis
Cryptogenic Organizing Pneumonia (COP)
Sarcoidosis
Acute Interstitial Pneumonitis
By Drug Type:
Corticosteroids
Anti-fibrotic Medication
Pirfenidone
Nintedanib
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
GCC
Israel
Rest of Middle East
Africa
By Disease Type:
Interstitial Pneumonia
Idiopathic Pulmonary Fibrosis
Nonspecific Interstitial Pneumonitis
Hypersensitivity Pneumonitis
Cryptogenic Organizing Pneumonia (COP)
Sarcoidosis
Acute Interstitial Pneumonitis
By Drug Type:
Corticosteroids
Anti-fibrotic Medication
Pirfenidone
Nintedanib
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country/Region:
South Africa
Central Africa
North Africa
Company Profiles
MSD (Merck) *
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Liminal Biosciences
Glenmark Pharma
J.B. Chemicals & Pharmaceuticals
Boehringer Ingelhim International GmbH
F. Hoffmann-La Roche Ltd
Cipla
“*” marked represents similar segmentation in other categories in the respective section.